1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : SPECIALTY PHARMACEUTICALS
  4. PHARMACYTE BIOTECH INC
PharmaCyte Biotech Inc
XNAS: PMCB
Download real time
0.76 0.00 (0.00%)
49.67% Fall from 52W High
85,563
XNAS Volume

XNAS 04 May, 2026 5:30 PM (EDT)

Watchlist

Portfolio

Alert


Insider Trading disclosures for PharmaCyte Biotech Inc

The latest disclosure was made by Robert Weinstein in PharmaCyte Biotech Inc where a trade of 119,170 Stock Option (Right to Buy) done was reported to US exchanges on March 31, 2026.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Robert Weinstein Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Mar 2026 119,170 119,170 - - Stock Option (Right to Buy)
Michael M. Abecassis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Mar 2026 119,170 119,170 - - Stock Option (Right to Buy)
Joshua Nathaniel Silverman Director, CEO and President Purchase of securities on an exchange or from another person at price $ 0.78 per share. 05 Jan 2026 30,000 346,250 - 0.8 23,493 Common Stock
Joshua Nathaniel Silverman Director, CEO and President Purchase of securities on an exchange or from another person at price $ 0.79 per share. 05 Jan 2026 30,000 376,250 - 0.8 23,667 Common Stock
Joshua Nathaniel Silverman Director, CEO and President Purchase of securities on an exchange or from another person at price $ 0.83 per share. 05 Jan 2026 40,000 416,250 - 0.8 33,316 Common Stock
Joshua Nathaniel Silverman Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Dec 2025 575,000 575,000 - 0 Common Stock
Joshua Nathaniel Silverman Director, CEO and President Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.02 per share. 12 Dec 2025 258,750 316,250 - 1.0 263,925 Common Stock
Robert Weinstein Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Apr 2025 75,000 75,000 - 0 Common Stock
Robert Weinstein Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.02 per share. 25 Apr 2025 33,750 41,250 - 1.0 34,425 Common Stock
Robert Weinstein Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Apr 2025 63,233 63,233 - - Stock Option (Right to Buy)
Michael M. Abecassis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Apr 2025 37,500 39,167 - 0 Common Stock
Michael M. Abecassis Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.02 per share. 25 Apr 2025 16,875 22,292 - 1.0 17,213 Common Stock
Michael M. Abecassis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Apr 2025 63,233 63,233 - - Stock Option (Right to Buy)
Robert Weinstein Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Apr 2024 38,009 38,009 - - Stock Option (Right to Buy)
Michael M. Abecassis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Apr 2024 38,009 38,009 - - Stock Option (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters